Trials / Completed
CompletedNCT01317641
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ODM-201 | ODM-201 administered orally daily |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2011-03-17
- Last updated
- 2017-03-29
- Results posted
- 2017-03-29
Locations
23 sites across 6 countries: United States, Czechia, Estonia, Finland, France, United Kingdom
Source: ClinicalTrials.gov record NCT01317641. Inclusion in this directory is not an endorsement.